Form 10-Q INOVIO PHARMACEUTICALS, For: Jun 30
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/13/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Super Micro Computer establishes $1.25 billion stock sale agreement
- Wall Street ends higher as SpaceX's market debut dominates
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- SpaceX Shares Indicated To Open At $155
Aegis Capital Comments on Inovio (INO) Following Q2 Results; Cash Position Remains 'Solid'
August 11, 2014 11:05 AM EDTAegis Capital affirms Inovio Pharmaceuticals (AMEX: INO) at Buy with a target price of $19 following Q2 results and update released earlier Monday.
Analyst Ram Selvaraju commented, This morning, Inovio reported financial results for the second quarter of 2014. The firm closed the... More
Inovio Pharmaceuticals (INO) Posts Narrower than Expected Q2 Loss of 18c/Share
August 11, 2014 9:17 AM EDTInovio Pharmaceuticals, Inc. (AMEX: INO) reported Q2 EPS of ($0.18), $0.01 better than the analyst estimate of ($0.19). Revenue for the quarter came in at $3.8 million versus the consensus estimate of $1.8 million.
Dr. J. Joseph Kim, President and CEO, said, "Our second quarter marked a historical... More
